About ERYtech Pharma
ERYtech Pharma is a publicly listed company based in Lyon (France) founded in 2004. Cancer therapeutics are developed through red blood cell encapsulation technology. ERYtech Pharma offers products and services including Phage Therapy and Individualized Phage Therapies.
Company details
ERYtech Pharma was founded in 2004 in Lyon, France, as a biopharmaceutical company focused on oncology. Therapeutics are developed by encapsulating molecules and enzymes within red blood cells to enhance delivery and minimize side effects. The ERYCAPS platform supports this approach, with a pipeline targeting tumor starvation, vaccination, and enzyme replacement. A lead product addresses acute leukemia in frail patients, emphasizing targeted cancer treatments.
- Headquarters Lyon, France
- Stage Public
- Website erytech.com
- Social LinkedIn X
- Latest Funding Round$74.6M (USD), Post-IPO
Apr 2017
- Investors
Products & Services of ERYtech Pharma
ERYtech Pharma offers a comprehensive portfolio of products and services, including Phage Therapy and Individualized Phage Therapies.
Uses bacteriophages to target and eradicate resistant bacteria
Develops tailored phage-based treatments for specific infections
Funding Insights of ERYtech Pharma
- Total Rounds 2
- Last Round Post-IPO — $74.6M
- Investors Count 1
All 2 funding rounds of ERYtech Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2017 | $74.6M | Post-IPO | – | – | – |
| Jun 2005 | Seed | – | – |
1 investors in total: 1 institutional.
Investors in ERYtech Pharma
ERYtech Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Karista.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Karista is recognized as an early-stage venture capital firm. | karista.vc |
Investor details for ERYtech Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ERYtech Pharma
8 people are tracked at ERYtech Pharma (4 in leadership, 4 in board & advisors).
| Name | Role | Group |
|---|---|---|
Karine Charton | Director, Innovation & Valorization | Leadership |
Anne-Cécile Fumey | Human Resources Director | Leadership |
Iman El-Hariry | Chief Medical Officer | Leadership |
Jérôme Bailly | Chief Quality Officer, Deputy General Manager & Qualified Person | Leadership |
Hilde Windels | Independent Director | Board & advisors |
Philippe Archinard | Independent Director | Board & advisors |
Leïla Nicolas | Independent Director | Board & advisors |
Didier Hoche | Independent Director | Board & advisors |
Complete people profiles for ERYtech Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ERYtech Pharma
4 dated milestones of ERYtech Pharma across 13 years, from founding to its latest funding, stage changes and deals.
- Founded ERYtech Pharma is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $74.6M.
Web traffic of ERYtech Pharma
Websites that share an audience with ERYtech Pharma (erytech.com).
Websites whose visitors overlap most with ERYtech Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
neovacs.fr | neovacs.fr | 100% | – | ||
investor.fiveprime.com | investor.fiveprime.com | 90% | – | ||
| syndax.com | 89% | 12.2K | #1,539,978 | View details | |
| epizyme.com | 89% | View details | |||
| medtrack.com | 89% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Erytech Pharma
Complete news archive for ERYtech Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ERYtech Pharma
ERYtech Pharma was founded in 2004 and raised its 1st funding round 1 year after it was founded.
ERYtech Pharma is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
ERYtech Pharma was founded in 2004 in Lyon, France, as a biopharmaceutical company focused on oncology. Therapeutics are developed by encapsulating molecules and enzymes within red blood cells to enhance delivery and minimize side effects. The ERYCAPS platform supports this approach, with a pipeline targeting tumor starvation, vaccination, and enzyme replacement. A lead product addresses acute leukemia in frail patients, emphasizing targeted cancer treatments.
ERYtech Pharma offers Phage Therapy and Individualized Phage Therapies.
ERYtech Pharma has 1 investor. Key investors include Karista.